Vera Therapeutics (NASDAQ:VERA) CFO Sean Grant Sells 4,949 Shares

Vera Therapeutics, Inc. (NASDAQ:VERA) CFO Sean Grant sold 4,949 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $207,759.02. Following the completion of the transaction, the chief financial officer directly owned 114,181 shares of the company’s stock, valued at approximately $4,793,318.38. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Vera Therapeutics Price Performance

Shares of VERA stock traded up $0.03 during mid-day trading on Thursday, hitting $41.71. The company had a trading volume of 358,376 shares, compared to its average volume of 1,001,433. The company has a debt-to-equity ratio of 0.19, a current ratio of 12.21 and a quick ratio of 12.21. The stock’s 50 day moving average price is $46.63 and its 200-day moving average price is $35.30. Vera Therapeutics, Inc. has a 52-week low of $18.53 and a 52-week high of $56.05. The company has a market capitalization of $2.92 billion, a P/E ratio of -10.49 and a beta of 1.16.

Vera Therapeutics News Summary

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: Late-stage clinical and regulatory wins: Vera reported positive Phase 3 ORIGIN 3 data for atacicept in IgA nephropathy, the results were presented at ASN Kidney Week and published in the New England Journal of Medicine. The FDA granted priority review to the atacicept BLA and set a PDUFA date of July 7, 2026; the company expects a potential U.S. commercial launch in mid‑2026. Management also says recent 2025 equity and debt financings leave the company well-funded into and beyond launch — a major de‑risking for revenue expectations. Read More.
• Neutral Sentiment: Quarterly results: VERA posted an adjusted EPS loss of ($1.28) that beat consensus (‑$1.34) by $0.06, which reduces near‑term execution uncertainty but still reflects a wider year‑over‑year loss (prior period: ‑$0.72). The beat is modest and does not change the company’s path to commercialization-driven valuation. Read More.
• Negative Sentiment: Significant insider selling: Several senior executives sold shares on Feb 23 (CEO Marshall Fordyce sold 16,925 shares at ~$41.98, reducing his stake by ~6.2%; CFO, COO and other officers also sold). Concentrated insider sales can signal personal liquidity taking and may create short‑term selling pressure or investor caution despite the positive program news. Read More.

Analyst Ratings Changes

VERA has been the topic of several recent research reports. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a report on Friday, December 5th. Bank of America increased their price objective on shares of Vera Therapeutics from $48.00 to $66.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. HC Wainwright restated a “buy” rating and set a $90.00 target price on shares of Vera Therapeutics in a research report on Friday, November 28th. JPMorgan Chase & Co. reduced their price target on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating on the stock in a report on Friday, December 19th. Finally, Pivotal Research set a $73.00 price objective on Vera Therapeutics in a report on Friday, December 5th. Nine analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Vera Therapeutics has an average rating of “Moderate Buy” and an average price target of $77.18.

Institutional Trading of Vera Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in VERA. Virtu Financial LLC bought a new position in Vera Therapeutics during the 4th quarter worth about $297,000. Invesco Ltd. boosted its stake in shares of Vera Therapeutics by 193.3% during the fourth quarter. Invesco Ltd. now owns 89,851 shares of the company’s stock valued at $4,550,000 after purchasing an additional 59,219 shares in the last quarter. KVP Capital Advisors LP purchased a new position in Vera Therapeutics during the fourth quarter valued at approximately $1,656,000. XTX Topco Ltd bought a new position in Vera Therapeutics in the fourth quarter worth approximately $508,000. Finally, Virtus Investment Advisers LLC raised its stake in Vera Therapeutics by 5.7% in the fourth quarter. Virtus Investment Advisers LLC now owns 5,342 shares of the company’s stock worth $271,000 after buying an additional 290 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.